Xspray Pharma AB (SE:XSPRAY)
:XSPRAY
Want to see SE:XSPRAY full AI Analyst Report?
XSPRAY Stock Chart & Stats
kr31.20
kr0.60(1.95%)
At close: 4:00 PM EST
kr31.20
kr0.60(1.95%)
Day’s Range― - ―
52-Week Rangekr22.46 - kr62.33
Previous CloseN/A
Volume2.99K
Average Volume (3M)297.70K
Market Cap
kr1.22B
Enterprise Valuekr1.23B
Total Cash (Recent Filing)kr120.72M
Total Debt (Recent Filing)kr147.85M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.20
Shares Outstanding47,416,573
10 Day Avg. Volume602,659
30 Day Avg. Volume297,696
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-6.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.7
Revenue Forecast (FY)kr91.20M
Bulls Say, Bears Say
Bulls Say
Licensing-based Commercial ModelA partner/licensing business model reduces the need for a large in-house sales force and converts R&D into milestone, upfront, and royalty streams. That structure is durable: it limits fixed costs, scales via partner commercialization, and preserves capital while pursuing additional deals.
Proprietary Formulation Tech (HyNap)Owning a formulation platform targeted at oncology creates a sustainable competitive advantage for life‑cycle management of small molecules. Improving bioavailability and differentiating established drugs supports partner interest, repeatable deal flow, and durable IP-driven value creation.
Equity Cushion With Moderate LeverageA sizable equity base provides a multi-quarter buffer against ongoing R&D losses and cash burn, while moderate leverage keeps near-term insolvency risk lower. This financial cushioning supports continued development and partner negotiations over the coming months.
Bears Say
No Revenue Across PeriodsAbsence of product revenue means the company is wholly dependent on financing and partner deals to fund operations. Without recurring sales, operating leverage cannot be demonstrated and financial sustainability hinges on securing external cash or near-term licensing transactions.
Persistent Negative Free Cash FlowConsistent, material cash burn that tracks net losses (FCF to net income ~1.05) steadily erodes liquidity and shortens runway. This structural outflow requires fresh financing or milestone payments to maintain R&D programs and limits strategic optionality over 2–6 months.
Rising Debt And Sharply Negative ROEIncreasing debt combined with deeply negative ROE signals growing financing risk and shareholder value erosion. Higher leverage raises fixed obligations and reduces flexibility to fund trials or accept suboptimal partnerships without worsening returns or diluting equity.
Xspray Pharma AB News
XSPRAY FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was kr22.46 and its highest was kr62.33 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is kr1.22B.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is Aug 05, 2026 which is in 75 days.
How were Xspray Pharma AB’s earnings last quarter?
Currently, no data Available
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 47,416,573 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in SE:XSPRAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xspray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Cantargia AB
―